Exicure Inc（XCUR）の株式分析XCURExicure Inc

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Exicure Inc (XCUR) is not a good buy right now due to significant financial instability and compliance issues. The current price is $1.29, and the company has a negative forward P/E ratio of 0, indicating no earnings growth expectations. Additionally, insider selling has increased by 106.79% over the last month, suggesting a lack of confidence from those within the company. The main risk is the Nasdaq delisting notification due to failing to maintain a minimum stockholders' equity of $2.5 million, as Exicure reported only $2.1 million, which could severely impact its market presence and ability to raise funds.

1 analysts cover XCUR: 1 rate it Buy, 0 Hold and 0 Sell.